Tianjin Development (00882) announced that its indirectly held non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Company Ltd. (Lisheng Pharmaceutical), is projected to achieve a net profit attributable to shareholders of the listed company ranging from RMB4 billion to RMB4.4 billion for the 2025 fiscal year. This represents a significant increase of 116.77% to 138.44% compared to the profit of RMB1.85 billion recorded in the same period last year.

During the reporting period, the net profit after deducting non-recurring gains and losses is expected to be between RMB1.6 billion and RMB1.9 billion, up 55.34% to 84.47% from the previous year's figure of RMB1.03 billion. The basic earnings per share are forecasted to be in the range of RMB1.50 per share to RMB1.80 per share.

Throughout the reporting period, the company persistently intensified its market expansion efforts, leading to an improvement in product sales. Furthermore, the net profit attributable to shareholders of the listed company registered a substantial year-on-year increase, partly influenced by dividend income from Tianshili Biopharmaceutical Industry Group Co., Ltd.